Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Common Equity (2016 - 2025)

Celldex Therapeutics has reported Common Equity over the past 16 years, most recently at $527.2 million for Q4 2025.

  • Quarterly results put Common Equity at $527.2 million for Q4 2025, down 29.43% from a year ago — trailing twelve months through Dec 2025 was $527.2 million (down 29.43% YoY), and the annual figure for FY2025 was $527.2 million, down 29.43%.
  • Common Equity for Q4 2025 was $527.2 million at Celldex Therapeutics, down from $598.4 million in the prior quarter.
  • Over the last five years, Common Equity for CLDX hit a ceiling of $838.6 million in Q1 2024 and a floor of $182.3 million in Q2 2021.
  • Median Common Equity over the past 5 years was $424.3 million (2021), compared with a mean of $479.6 million.
  • Biggest five-year swings in Common Equity: skyrocketed 218.54% in 2024 and later fell 29.43% in 2025.
  • Celldex Therapeutics' Common Equity stood at $419.5 million in 2021, then decreased by 22.24% to $326.2 million in 2022, then soared by 31.57% to $429.2 million in 2023, then surged by 74.06% to $747.0 million in 2024, then fell by 29.43% to $527.2 million in 2025.
  • The last three reported values for Common Equity were $527.2 million (Q4 2025), $598.4 million (Q3 2025), and $655.4 million (Q2 2025) per Business Quant data.